Boston Scientific is a global medical technology company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and solutions. The company focuses on providing innovative therapies for various medical conditions, including those affecting the cardiovascular, urology, and gastrointestinal systems, among others. Boston Scientific is committed to advancing patient care through its pioneering technologies, which are designed to improve outcomes and enhance the quality of life for patients around the world. Their product offerings include devices for minimally invasive procedures, enabling healthcare professionals to deliver high-quality care efficiently and effectively. Read More
BOSTON SCIENTIFIC CORP (NYSE:BSX) shows strong technicals and a high-quality setup, making it a breakout candidate. The stock has outperformed peers and exhibits bullish patterns with clear support and resistance levels.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
See these three stocks that beat on earnings in Q1 and raised their guidance for the rest of 2025. These stocks are signaling strength amid tough conditions.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q1 CY2025, with sales up 20.9% year on year to $4.66 billion. The company expects next quarter’s revenue to be around $4.88 billion, close to analysts’ estimates. Its non-GAAP profit of $0.75 per share was 11.5% above analysts’ consensus estimates.
Shares of medical device company Boston Scientific (NYSE:BSX)
jumped 8.5% in the pre-market session after the company reported first quarter 2025 results that beat analysts' sales and EPS expectations. Organic sales growth topped the company's own forecast and was led by a 25.6% surge in its Cardiovascular segment, a signal that demand in its largest business is accelerating.
Looking ahead, its revenue guidance for next quarter exceeded Wall Street's estimates. Overall, we think this was a decent quarter with some key metrics above expectations.
Risk-on sentiment dominated Wall Street on Wednesday, as upbeat earnings reports and conciliatory messages from the Trump administration helped lift investor confidence.
Medical device company Merit Medical Systems (NASDAQ:MMSI)
will be announcing earnings results tomorrow after the bell. Here’s what investors should know.
Medical device company Boston Scientific (NYSE:BSX) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 20.9% year on year to $4.66 billion. Guidance for next quarter’s revenue was better than expected at $4.88 billion at the midpoint, 2% above analysts’ estimates. Its non-GAAP profit of $0.75 per share was 11.5% above analysts’ consensus estimates.
